These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50 related articles for article (PubMed ID: 14001333)
1. Protein interactions of sulfonylurea compounds. WISHINSKY H; GLASSER EJ; PERKAL S Diabetes; 1962; 11(Suppl)():18-25. PubMed ID: 14001333 [No Abstract] [Full Text] [Related]
2. Clinical experience with sulphonylureas. AHUJA MM J Indian Med Assoc; 1962 Sep; 39():221-8. PubMed ID: 14011382 [No Abstract] [Full Text] [Related]
3. CHOLESTATIC JAUNDICE FOLLOWING USE OF SULFONYLUREA DRUGS. COLLENS WS; DOBKIN GB N Y State J Med; 1965 Apr; 65():907-9. PubMed ID: 14265335 [No Abstract] [Full Text] [Related]
4. EFFECT OF ORAL SULFONYLUREA ON PLASMA TRIGLYCERIDES IN DIABETICS. MORRIS JH; WEST DA; BOLINGER RE Diabetes; 1964; 13():87-9. PubMed ID: 14104182 [No Abstract] [Full Text] [Related]
7. CORNEAL AND LENTICULAR OPACITIES IN THE EYES OF RATS FOLLOWING LONG-TERM ADMINISTRATION OF SULFONYLUREA DERIVATIVES. A PRELIMINARY REPORT. WRIGHT HN Diabetes; 1963; 12():550-4. PubMed ID: 14075328 [No Abstract] [Full Text] [Related]
8. SULPHONYLUREA DRUGS IN PREGNANCY. MALINS JM; COOKE AM; PYKE DA; FITZGERALD MG Br Med J; 1964 Jul; 2(5402):187. PubMed ID: 14153903 [No Abstract] [Full Text] [Related]
9. Displacement of phenprocoumon (Marcumar) from albumin by sulfonylurea compounds, suramin, and ioglycamic acid. Hüthwohl B; Jähnchen E Naunyn Schmiedebergs Arch Pharmacol; 1972; 273(3):204-12. PubMed ID: 4261772 [No Abstract] [Full Text] [Related]
10. The binding of sulphonylureas to serum albumin. Crooks MJ; Brown KF J Pharm Pharmacol; 1974 May; 26(5):304-11. PubMed ID: 4153105 [No Abstract] [Full Text] [Related]
11. Estimation of phenytoin in body fluids in the presence of sulphonyl urea compounds. Thürkow I; Wesseling H; Meijer DK Clin Chim Acta; 1972 Mar; 37():509-13. PubMed ID: 5022115 [No Abstract] [Full Text] [Related]
12. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710 [TBL] [Abstract][Full Text] [Related]
14. [Studies on the formation of side products in the synthesis of tolbutamide using thin-layer chromatography]. Menzer M; Prezewowski J; Haug U Pharmazie; 1971 Dec; 26(12):738-9. PubMed ID: 5141255 [No Abstract] [Full Text] [Related]
15. Investigation of the effects of sulfonylurea exposure on pancreatic beta cell metabolism. Brennan L; Hewage C; Malthouse JP; McClenaghan NH; Flatt PR; Newsholme P FEBS J; 2006 Nov; 273(22):5160-8. PubMed ID: 17054712 [TBL] [Abstract][Full Text] [Related]
16. [Oral medication of diabetes mellitus]. CANIVET J Cah Coll Med Hop Paris; 1962 Aug; 3():537-43. PubMed ID: 14018301 [No Abstract] [Full Text] [Related]
17. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. Becker ML; Aarnoudse AJ; Newton-Cheh C; Hofman A; Witteman JC; Uitterlinden AG; Visser LE; Stricker BH Pharmacogenet Genomics; 2008 Jul; 18(7):591-7. PubMed ID: 18551039 [TBL] [Abstract][Full Text] [Related]
18. [Binding of SPC-703 and tolbutamide to albumin]. Wójcikowski C; Szlabowicz D Endokrynol Pol; 1976; 27(1):37-43. PubMed ID: 1253758 [No Abstract] [Full Text] [Related]